Gilead’s HCV Drug Sofosbuvir Approved by the FDA but Accessible for How Many?
Press Release – 9 December 2013 / Bangkok – Paris – Basel – London – New York
On 6 Dec 2013, FDA approved Gilead’s HCV drug Sovaldi. Yet its anticipated price tag of $80,000 will ensure this drug remains out of reach for the vast majority of people with HCV. More
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Bangkok, Thailand, 28 February 2014
Activists from 22 countries joined forces at the first-ever HCV World CAB to demand equitable access to HCV treatment from six multinational pharmaceutical companies. More
International Liver Conference: Activists Demand Affordable Hepatitis C Treatment
Pills cost pennies, greed costs lives.
As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in LMICs. More
AIDS 2014: Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
"HCV drugs are priced out of reach and out of control", Michel Sidibé, UNAIDS
Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C drug. More
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More